Medtech Ortho Franchise — Restructuring
Johnson & Johnson Medtech Ortho Franchise — Restructuring remained flat by 0.0% to $38.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 15.2%, from $33.00M to $38.00M. Over 2 years (FY 2023 to FY 2025), Medtech Ortho Franchise — Restructuring shows a downward trend with a -26.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase suggests active efforts to streamline operations or integrate new technologies, while a decrease may indicate the completion of a restructuring phase.
Detailed definition
This metric represents the specific costs or financial impacts associated with organizational realignment, operational s...
Peer comparison
Peers in the medical device industry often report these as 'restructuring charges' or 'special items' within segment-level operating expenses, making them comparable to similar transformation costs at companies like Stryker or Zimmer Biomet.
jnj_segment_medtech_ortho_franchise_restructuringHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $279.00M | $132.00M | $152.00M |
| YoY Change | — | -52.7% | +15.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's medtech ortho franchise — restructuring?
- Johnson & Johnson (JNJ) reported medtech ortho franchise — restructuring of $38.00M in Q4 2025.
- How has Johnson & Johnson's medtech ortho franchise — restructuring changed year-over-year?
- Johnson & Johnson's medtech ortho franchise — restructuring increased by 15.2% year-over-year, from $33.00M to $38.00M.
- What is the long-term trend for Johnson & Johnson's medtech ortho franchise — restructuring?
- Over 2 years (2023 to 2025), Johnson & Johnson's medtech ortho franchise — restructuring has grown at a -26.2% compound annual growth rate (CAGR), from $279.00M to $152.00M.
- What does medtech ortho franchise — restructuring mean?
- The costs associated with reorganizing and improving the efficiency of the Orthopedics business segment.